Oslo, Norway, 7 January 2022

Nordic Nanovector ASA (OSE: NANOV) provides an update on the timeline for
PARADIGME, its ongoing pivotal Phase 2b trial of Betalutin[® ]([177]Lu lilotomab
satetraxetan) in 3[rd]-line relapsed rituximab/anti-CD20 refractory follicular
lymphoma (3L R/R FL). The Company reports that 106 patients have been enrolled
into PARADIGME as of 6 January 2022.

Given the ongoing impact from the SARS-CoV-2 omicron variant on patient
recruitment, the Company now anticipates the preliminary three-month data
readout from PARADIGME to be reported during the second half of 2022 (previously
first half of 2022).

As communicated on 3 August 2021, the changes to the PARADIGME protocol and
other initiatives implemented by the Company have positively impacted execution
of the PARADIGME trial. However, the ongoing COVID pandemic, exacerbated by the
rapid spread of the new omicron variant of SARS-COV-2, has continued to affect
the Company's ability to screen, enrol and treat new patients whose physical
condition means they are at the greatest risk from COVID-19 infection.

Despite this challenging situation, Nordic Nanovector continues to work
diligently towards the completion of PARADIGME, which remains the Company's key
strategic priority for 2022.

Erik Skullerud, Chief Executive Officer of Nordic Nanovector, commented: "We are
experiencing an unexpected significant impact of the new SARS-CoV-2 omicron
variant on the enrolment rate of our clinical trial. However, we now have the
end in sight, and I am confident that we can deliver the important preliminary
data from this study during the second half of 2022."

For further information, please contact:

IR enquiries

Malene Brondberg, CFO
Cell: +44 7561 431 762
Email: ir@nordicnanovector.com

Media Enquiries

Mark Swallow/Frazer Hall (MEDiSTRAVA Consulting)
Tel: +44 203 928 6900
Email: nordicnanovector@medistrava.com

About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
Company aspires to become a leader in the development of targeted therapies for
haematological cancers. Nordic Nanovector's lead clinical-stage candidate is
Betalutin[®], a novel CD37-targeting radioimmunotherapy designed to advance the
treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial
unmet medical need, representing a growing market forecast to be worth nearly
USD 29 billion by 2026. Nordic Nanovector retains global marketing rights to
Betalutin[®] and intends to actively participate in the commercialisation of
Betalutin[®] in the US and other major markets.

Further information can be found at www.nordicnanovector.com.

Forward-looking statements

This press release contains certain forward-looking statements. These statements
are based on management's current expectations and are subject to uncertainty
and changes in circumstances, since they relate to events and depend on
circumstances that will occur in the future and which, by their nature, will
have an impact on Nordic Nanovector's business, financial condition and results
of operations. The terms "anticipates", "assumes", "believes", "can", "could",
"estimates", "expects", "forecasts", "intends", "may", "might", "plans",
"should", "projects", "targets", "will", "would" or, in each case, their
negative, or other variations or comparable terminology are used to identify
forward-looking statements. These forward-looking statements are not historic
facts. There are a number of factors that could cause actual results and
developments to differ materially from those expressed or implied in the forward
-looking statements. Factors that could cause these differences include, but are
not limited to, risks associated with implementation of Nordic Nanovector's
strategy, risks and uncertainties associated with the development and/or
approval of Nordic Nanovector's product candidates, ongoing and future clinical
trials and expected trial results, the ability to commercialise Betalutin®,
technology changes and new products in Nordic Nanovector's potential market and
industry, Nordic Nanovector's freedom to operate (competitors patents) in
respect of the products it develops, the ability to develop new products and
enhance existing products, the impact of competition, changes in general economy
and industry conditions, and legislative, regulatory and political factors. No
assurance can be given that such expectations will prove to have been correct.
Nordic Nanovector disclaims any obligation to update or revise any forward
-looking statements, whether as a result of new information, future events or
otherwise.

This information is subject to a duty of disclosure pursuant to Sections 4-2 and
5-12 of the Securities Trading Act.

Click here for more information

© Oslo Bors ASA, source Oslo Stock Exchange